Heart failure is a serious and widespread condition that affects millions of people worldwide. It occurs when the heart can’t ...

There is an unmet need for therapies targeting Duchenne muscular dystrophy (DMD)–related heart disease, and phase 2 results ...

Heart failure remains a substantial burden for patients due to its high prevalence and limited therapeutic options. Heart ...

Heart failure remains a substantial burden for patients due to its high prevalence and limited therapeutic options. Heart failure is classified into two major clinical subtypes- heart failure with ...

Patients with rheumatoid arthritis are associated with an increased risk for heart failure, particularly heart failure with preserved ejection fraction.

Danielle Rasooly, PhD, of the Division of Aging at Brigham and Women’s Hospital, is the co-corresponding author of a paper published in Nature Cardiovascular Research, “Large-scale multi-omics ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

The key to treating congestive heart failure is addressing the underlying causes, and treatment is highly tailored to each patient's needs. Chris Bell, an acute care nurse practitioner who specializes ...

Middle aged and older adults who are hospitalized for severe infections were more than twice as likely to develop heart failure in the future, a new study shows. Authors say that’s why it’s so ...

Cytokinetics , Inc. (NASDAQ:CYTK), with a market capitalization of $5.65 billion, is approaching a pivotal moment in its journey to become a leading player in the cardiovascular therapeutics market.

Researchers discovered that ALPK2, a heart-specific enzyme, may protect against HFpEF by activating TPM1 in heart muscle ...